Want to see BJDX full AI Analyst Report?
BJDX Stock Chart & Stats
$0.65
-$0.20(-5.19%)
At close: 4:00 PM EST
$0.65
-$0.20(-5.19%)
Day’s Range― - ―
52-Week Range$1.03 - $16.68
Previous CloseN/A
Volume34.54K
Average Volume (3M)5.27M
Market Cap
$1.39M
Enterprise Value-$1.57M
Total Cash (Recent Filing)$3.68M
Total Debt (Recent Filing)$97.03K
Price to Earnings (P/E)―
Beta-0.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,034,715
10 Day Avg. Volume15,571,172
30 Day Avg. Volume5,266,425
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.00
Enterprise Value/Ebitda0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal SYMON‑II Enrollment Nearing CompletionNear-complete pivotal enrollment materially shortens the regulatory pathway timeline and reduces clinical execution risk. Successful completion enables analysis to support a 510(k), strengthening the firm’s ability to commercialize a rapid IL-6 sepsis diagnostic and convert R&D investment into a marketable product.
Manufacturing Readiness And Inventory ScaleEstablished cartridge characterization and antibody supply for >10M cartridges indicate manufacturing scale preparedness, lowering commercialization and supply‑chain risks. A no-single-point-of-failure transfer strategy further reduces operational bottlenecks and supports durable commercial launch capabilities.
Low Leverage And Restored Equity PositionVery low debt and positive equity reduce refinancing pressure and financial fragility. Compared with earlier periods of negative equity, the repaired balance sheet gives the company more runway and flexibility to fund regulatory and commercialization activities without excessive interest or covenant constraints.
Bears Say
Persistent Negative Cash FlowSustained multi‑million negative operating and free cash flow creates ongoing funding needs and heightens execution risk until revenue materializes. Even with some improvement, persistent burn compels dilution or external financing, limiting ability to invest opportunistically in commercialization or scale.
Minimal Revenue And Recurring Net LossesAbsent meaningful revenue and repeated multi‑million losses mean the business has yet to demonstrate commercial traction or sustainable margins. Continued negative earnings erode equity over time and leave performance hinging on successful product approval and subsequent adoption.
Funding And Dilution OverhangOutstanding cash‑exercisable warrants and small insider financings signal ongoing reliance on equity capital. With high cash burn and limited cash raises to date, future financings are probable, creating dilution risk and potential distractions for management during critical clinical and regulatory milestones.
Bluejay Diagnostics News
BJDX FAQ
What was Bluejay Diagnostics’s price range in the past 12 months?
Bluejay Diagnostics lowest stock price was $1.03 and its highest was $16.68 in the past 12 months.
What is Bluejay Diagnostics’s market cap?
Bluejay Diagnostics’s market cap is $1.39M.
When is Bluejay Diagnostics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bluejay Diagnostics’s earnings last quarter?
Currently, no data Available
Is Bluejay Diagnostics overvalued?
According to Wall Street analysts Bluejay Diagnostics’s price is currently Overvalued.
Does Bluejay Diagnostics pay dividends?
Bluejay Diagnostics does not currently pay dividends.
What is Bluejay Diagnostics’s EPS estimate?
Bluejay Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bluejay Diagnostics have?
Bluejay Diagnostics has 1,034,715 shares outstanding.
What happened to Bluejay Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bluejay Diagnostics?
Currently, no hedge funds are holding shares in BJDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bluejay Diagnostics
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Technical Analysis
Ownership Overview
6.08% Insiders
0.88% Mutual Funds
2.79% Other Institutional Investors
90.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---